Close Menu

Artemis Health

Anticipating that NGS will become a key clinical tool in coming years, several proteomics firms and researchers are investigating it as a platform for protein biomarker detection assays that use nucleotides as capture agents, hoping to take advantage of the technology's precision and multiplexing ability.

In Brief This Week is a Friday column containing news items that our readers may have missed during the week.

Using a sequencing method and proprietary algorithm based on technology licensed from Stephen Quake at Stanford University, the researchers correctly identified all trisomy 21 and trisomy 18 cases.

Caren Mason

A bioethicist argues that it is now time to start taking steps to consider how to handle ethical, social, and legal issues that loom over non-invasive prenatal genetic tests.

Companies developing DNA sequencing and related technologies, as well as firms working on sequencing-based genetic tests, were among almost 3,000 small biotechs who received a total of $1 billion in grants and tax credits under the QTDP program.

US tax agency says 23andMe's genetic health test can be claimed as a medical expense for tax purposes, the Wall Street Journal reports.

The Guardian reports that some UK physicians are calling for increased regulation of direct-to-consumer genetic tests.

Two Democratic lawmakers argue at USA Today that independent science is under attack by the Trump Administration.

In PLOS this week: networks of genes co-expressed in depression, role of minichromosome maintenance genes in lung adenocarcinoma, and more.